Antibodies raises £400k in pre-seed funding led by Nidobirds Ventures to expand its reagent catalogue and scale technology.

Antibodies has secured £400k in a pre-seed funding round led by Nidobirds Ventures, with participation from local angel investors and industry veterans. The company will direct the capital towards expanding its catalogue of off-the-shelf reagents, implementing new customer acquisition initiatives, and scaling its proprietary artificial intelligence tool.

The marketplace aims to address widespread inefficiencies in life science research by offering reliable reagents significantly faster and cheaper than traditional procurement methods. Since leaving beta, the firm has partnered with over 50 supply chain suppliers and serves major pharmaceutical companies and academic institutions across North America and Europe.